Methotrexat STADA is a medication used in the management of several specified conditions. Its primary applications fall within therapeutic domains where a systemic approach is indicated.

Quick Facts

• Active Rheumatoid Arthritis: Utilized for managing active rheumatoid arthritis in adult patients.
• Polyarthritic Juvenile Idiopathic Arthritis (JIA): An option for treating specific severe forms of JIA in children aged 3 and older.
• Psoriasis and Psoriatic Arthritis: Employed to address severe, disabling forms of plaque psoriasis and psoriatic arthritis in adults when other treatments are not suitable or have not yielded an adequate response.
• Oncologic Uses: Indicated for the maintenance management of acute lymphoblastic leukemia (ALL) as part of complex therapeutic protocols.

The use of this medication in these various patient populations is intended to assist in managing disease activity and may contribute to a reduction in symptoms associated with these chronic conditions.

Official Eligibility and Non-Eligibility Rules

Methotrexat STADA's use is strictly defined by regulatory criteria, encompassing specific approved populations and absolute prohibitions (contraindications) based on patient health status and physiology.

Population Status
Populations for Whom Use is Allowed
Adults with active rheumatoid arthritis, severe psoriasis, or psoriatic arthritis.
Pediatric patients aged 3 years and older for certain conditions like juvenile idiopathic arthritis (JIA) and maintenance therapy for acute lymphoblastic leukemia (ALL).
Populations for Whom Use is Contraindicated
Pregnancy and breastfeeding (absolute prohibition due to embryo-fetal toxicity risk).
Patients with severe hepatic impairment (severe liver disease) or severe renal impairment (severe kidney disease).
Individuals with a history of alcoholism, severe blood disorders (e.g., leukopenia, thrombocytopenia), or a history of severe hypersensitivity to methotrexate.
Patients with active, severe infections, active gastrointestinal ulcers (e.g., stomatitis, peptic ulceration), or those receiving live vaccines.

Age-Related and Conditional Use
Use Not Recommended
Children under 3 years old for non-oncologic indications due to insufficient data on safety and efficacy.
Conditional/Restricted Use
Older adults (ge 65 years) require careful monitoring due to the potential for reduced organ function.
Patients with mild-to-moderate renal or hepatic impairment may require close monitoring and possible adjustment.

Interactions with other medicines and products

Methotrexat STADA can interact with various other medicines and substances, potentially leading to increased Methotrexate concentrations and toxicity. Concomitant use with certain products is specifically restricted or contraindicated based on regulatory requirements.

---

Key Interacting Agents and Substance Classes

The following are significant interacting classes or products:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Salicylates: These may significantly reduce the renal elimination of Methotrexate, leading to elevated and prolonged serum levels and severe toxicity. Use with high-dose Methotrexate regimens is generally avoided.
• Antibiotics: Penicillins and ciprofloxacin, among others, can decrease Methotrexate's renal clearance. Sulfonamides and tetracyclines may also interact by inhibiting protein binding.
• Proton Pump Inhibitors (PPIs): Medicines like omeprazole can inhibit the renal clearance of Methotrexate, particularly increasing the risk of toxicity in patients receiving high-dose treatment.
• Highly Protein-Bound Drugs: Medications such as phenytoin and warfarin may displace Methotrexate from plasma protein binding, increasing the free Methotrexate concentration.
• Nitrous Oxide: Combination with nitrous oxide anesthesia is contraindicated due to its effect on folate metabolism, which can lead to severe myelosuppression and neurotoxicity.
• Hepatotoxic Agents and Alcohol: Co-administration with other hepatotoxic drugs, such as acitretin (which is contraindicated), or excessive alcohol intake increases the risk of liver damage.

---

Interaction-Related Monitoring Requirements

When Methotrexat STADA is used with interacting medicines, close monitoring of Methotrexate serum levels, renal function, and hematologic parameters is frequently mandated to detect potential toxicity.

Antimetabolite Action and Inhibition of Cell Proliferation

Methotrexate functions as a folic acid antagonist, primarily through the competitive inhibition of the enzyme dihydrofolate reductase (DHFR). This molecular action restricts the conversion of dihydrofolate into its active form, tetrahydrofolate, a crucial co-factor for nucleotide synthesis. The resulting depletion of these precursors impairs DNA and RNA production, exerting an antiproliferative (cytostatic) effect that inhibits the rapid division of immune cells, particularly activated lymphocytes.

---

Immunomodulation Through Adenosine Signaling

A distinct, secondary mechanism involves the inhibition of AICAR transformylase (ATIC), which promotes the accumulation and enhanced release of extracellular adenosine. This endogenous signaling molecule activates specific adenosine receptors (A2 and A3) on inflammatory cells. Receptor activation leads to a reduction in immune cell function, limits their migration, and decreases the production of pro-inflammatory chemical messengers. This pathway establishes a basis for systemic modulation of immune activity.

---

Cascade Dynamics and Gradual Modulation

The full pharmacological effect is not immediate because the mechanism relies on slow, multi-step intracellular cascades. This includes the time-dependent accumulation of the drug's active polyglutamates within cells and the chronic modulation of the adenosine signaling pathway. This process dictates that the full extent of immune modulation is achieved gradually over weeks to months.

Administration Principles

The administration of Methotrexat STADA is governed by specific protocols. For non-oncologic indications like rheumatoid arthritis and psoriasis, the medicine is indicated for once-weekly administration; daily use is strictly prohibited for these chronic inflammatory conditions. The approved routes include oral tablets and parenteral injection (subcutaneous, intramuscular, or intravenous).

Oral tablets must be swallowed whole and should not be crushed, split, or chewed, which is a required condition for proper usage. The injectable forms are supplied ready-to-use for parenteral administration.

---

Official Dosing and Regimens

The standard regimen for adult rheumatoid arthritis typically commences with a low dose, such as 7.5 mg once weekly, which is then titrated but must not exceed the specified maximum weekly dose (e.g., 20 mg to 30 mg). For pediatric patients with conditions like Juvenile Idiopathic Arthritis, the dose is calculated based on body surface area (BSA). The total weekly dose may sometimes be administered as a single dose or divided into three equal doses given 12 hours apart, repeated once per week.

---

Procedural Conditions

An essential procedural component of the usage protocol is the concomitant, separate administration of folic acid or folinic acid supplementation, which is integrated into the overall treatment plan. Furthermore, standard protocols involve the dose being carefully adjusted or withheld in patients with renal impairment based on their measured creatinine clearance. These instructions define the standardized approach to using the medicine.

Methotrexat STADA: Recent Clinical Evidence

The information below summarizes the types of research and clinical studies that contribute to the current evidence landscape for Methotrexat STADA (methotrexate). This overview is based on findings reported in authoritative government and peer-reviewed scientific sources.

---

Evidence Base for Inflammatory Conditions

Research exploring the use of this medicine in conditions like Active Rheumatoid Arthritis (RA) is supported by a high volume of Randomized Controlled Trials (RCTs). Studies were designed to examine outcomes in adults, focusing on measures of disease activity (such as ACR criteria) and patient-reported outcomes describing daily functioning or activity level. Research findings describe patterns observed in these studies regarding joint tenderness and swelling.

For Severe Psoriasis and Psoriatic Arthritis (PsA), studies included RCTs that tracked standardized measures of skin lesion severity (PASI score) and joint disease activity (ACR20). Findings for PsA joint outcomes have been described as mixed in some meta-analyses, indicating that the certainty remains low for certain aspects of joint response.

The medicine was also evaluated in studies involving children and young people with Juvenile Idiopathic Arthritis (JIA), using specialized pediatric-specific response criteria. Furthermore, methotrexate was studied for use in complex, multi-drug therapeutic protocols for Oncologic Protocols, where studies monitored outcomes related to Overall Survival (OS) and Event-Free Survival (EFS).

---

Areas Where Research Remains Limited

Despite the breadth of the research, several limitations exist. Comparative evidence is lacking for direct trials against all the newer targeted biologic therapies now available for inflammatory conditions. Furthermore, the evidence is limited for very long-term outcomes. While patient registries provide data on the duration of therapy use, long-term effects are not fully established through the same high-certainty methods used in short-term RCTs. Data for how sustained changes in disease activity continue over five or more years is primarily derived from these observational sources, and certainty remains low for certain patient subgroups.

Common questions about Methotrexat STADA (FAQ)

Q: What happens if you miss a dose of Methotrexat STADA?

A: If a dose is missed, official information indicates that a healthcare professional should be contacted immediately. Because Methotrexat STADA is typically taken only once a week for inflammatory conditions, regulatory warnings caution against taking an extra or double dose to make up for the missed one. The decision regarding how to proceed must be made by a doctor or pharmacist.

Q: Can men or women take Methotrexat STADA if they plan to start a family soon?

A: Official information states that Methotrexat STADA is contraindicated during pregnancy due to the risk of fetal harm. Regulatory documents state that women of childbearing potential are required to use effective contraception during treatment and for at least six months after stopping the medication. Men are also included in the contraception requirements outlined in the product label for at least three months after the final dose.

Q: What is the connection between Methotrexat STADA and lung problems?

A: The official warnings indicate that Methotrexat STADA carries a risk of causing lung toxicity (pneumonitis), which can be severe. The appearance of new pulmonary symptoms (such as dry cough or shortness of breath) requires prompt medical evaluation, and the official label requires the medication to be discontinued under these circumstances to prevent potential complications.

Q: Does Methotrexat STADA make you more susceptible to catching colds or the flu?

A: As an immunosuppressant, Methotrexat STADA works by modulating the immune system, which may increase the risk of serious infections. Official warnings emphasize the importance of monitoring for signs of infection and informing a healthcare provider if they occur, due to the drug’s mechanism of action.

Q: Are there specific vaccines to avoid while taking Methotrexat STADA?

A: Official safety information contraindicates the use of Methotrexat STADA concurrently with live vaccines. Because the medicine affects the immune response, the body may not be able to develop proper immunity to a live vaccine, and there is a documented risk of severe infection.

Q: What should I do if I experience a stomach upset from Methotrexat STADA?

A: Gastrointestinal issues, such as nausea, vomiting, or diarrhea, are listed as common side effects. Regulatory warnings state that severe or persistent symptoms, such as severe vomiting or diarrhea, require prompt reporting to a healthcare provider. The official information cautions that these symptoms may indicate toxicity.

Q: Does Methotrexat STADA cause sun sensitivity?

A: The official patient information suggests that Methotrexat STADA can increase skin sensitivity to sunlight, known as photosensitivity. Official patient information often includes recommendations to limit sun exposure, wear protective clothing, and use sunscreens during therapy.

Q: Can Methotrexat STADA be used in pediatric patients?

A: Yes, Methotrexat STADA is approved for use in certain pediatric patients who are typically three years of age and older. This includes its use for conditions like Juvenile Idiopathic Arthritis (JIA) and as part of the maintenance therapy for Acute Lymphoblastic Leukemia (ALL).

Q: Can Methotrexat STADA cause mood changes or depression?

A: While not a universally common effect, some official patient information sources list possible adverse effects related to the central nervous system, such as dizziness or tiredness. Less common occurrences may include reports of mood changes or symptoms of depression.

Q: Is it safe to drive or operate machinery while taking Methotrexat STADA?

A: Official labeling advises that if individuals experience side effects like dizziness, fatigue, or somnolence (sleepiness), they should be cautious about driving or operating machinery, as these effects can impair ability. The decision to drive should be based on the absence of these side effects.

Q: Is there a link between Methotrexat STADA and headaches?

A: Yes, regulatory documents list headache as a common side effect of Methotrexat STADA. A common side effect is defined as one that may affect up to 1 in 10 people.

Q: What resources are available for patients starting Methotrexat STADA therapy?

A: Official health authorities mandate that patients receive comprehensive materials, such as a Patient Information Leaflet or Medication Guide. These resources provide essential information on the proper administration, required monitoring tests, potential risks, and safety warnings for Methotrexat STADA.

Q: How quickly does Methotrexat STADA start working for psoriasis?

A: Studies and official patient guides indicate that the full therapeutic effect is not immediate. For chronic inflammatory conditions like psoriasis, it may take between three to six weeks for a patient to begin noticing improvements in their symptoms, with the full therapeutic response potentially taking twelve weeks or longer.

Q: Does Methotrexat STADA interact with common pain relievers like ibuprofen?

A: Yes, official safety information highlights a significant interaction risk with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. Combining these medicines can reduce the body's ability to eliminate methotrexate, potentially leading to elevated, toxic concentrations of the drug.

Q: How does Methotrexat STADA affect the mucous membranes in the mouth?

A: The medicine is commonly associated with side effects that affect the mucous membranes. Specifically, Methotrexat STADA can cause stomatitis, which is the inflammation of the lining of the mouth, often resulting in painful sores or ulcers.

Storage and Handling Requirements

Methotrexat STADA must be stored below 25 C and protected from light by keeping it in the original outer carton. The solution for injection must not be frozen. If using a multi-dose vial, it must be stored under refrigeration (2 C to 8 C) and used within 30 days after the first puncture.

All forms of the medicine, including pre-filled syringes and associated sharps disposal containers, must be kept out of the reach and sight of children, as accidental exposure can be lethal.

Official Disposal Instructions

Methotrexat STADA is classified as a hazardous drug. Any unused or expired product and all waste materials, particularly used needles and syringes, must be disposed of as cytotoxic waste in accordance with local regulations. It must not be discarded in household trash or down the drain, but should be returned to a pharmacy or collection facility for final disposal by incineration.